Headquartered in Boston, MA Fiscal year ends December AKTS aktisoncology.com
Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals using a proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver radioisotopes such as actinium-225 to tumors. The company's platform is engineered for high tumor penetration, internalization, and retention in cancer cells while rapidly clearing from normal tissues, and enables clinicians to visualize target engagement with imaging isotopes before administering therapeutic doses. Aktis's most advanced program, AKY-1189, targets Nectin-4 in urothelial cancer, breast cancer, and other solid tumors, while its second clinical program, AKY-2519, targets B7-H3 in prostate, lung, and other solid tumors. The company also maintains a discovery collaboration with Eli Lilly and Company to develop novel radioconjugates outside its proprietary pipeline. Aktis completed its initial public offering in January 2026 and trades on NASDAQ under the ticker AKTS. Updated
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.
Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals using a proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver radioisotopes such as actinium-225 to tumors.
The Wall Street consensus 12-month price target for AKTS is $35.39.
